Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Metadata
Title
C-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells
Authors
E. Gregory MacEwen
Jon Kutzke
Jennifer Carew
Josep Pastor
Julie A. Schmidt
Rachel Tsan
Douglas H. Thamm
Robert Radinsky
Publication date
01-09-2003
Publisher
Kluwer Academic Publishers
Published in
Clinical & Experimental Metastasis / Issue 5/2003
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1023/A:1025404603315

Other articles of this Issue 5/2003

Clinical & Experimental Metastasis 5/2003 Go to the issue

OriginalPaper

Activity of biphenyl matrix metalloproteinase inhibitor BAY 12-9566 in a human breast cancer orthotopic model

OriginalPaper

Inhibition of αvβ3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases

OriginalPaper

Seprase, a membrane-bound protease, alleviates the serum growth requirement of human breast cancer cells

OriginalPaper

Breast cancer micrometastases: Different interactions of carcinoma cells with normal and cancer patients' bone marrow stromata

OriginalPaper

Continuous real time ex vivo epifluorescent video microscopy for the study of metastatic cancer cell interactions with microvascular endothelium

OriginalPaper

Reduced angiogenesis in peritoneal dissemination of gastric cancer through gelatinase inhibition
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits